Literature DB >> 35513433

Increased intracellular Cl- concentration mediates neutrophil extracellular traps formation in atherosclerotic cardiovascular diseases.

Hui Han1, Chang Liu1, Mei Li2, Jin Wang3, Yao-Sheng Liu1, Yi Zhou3, Zi-Cheng Li1, Rui Hu1, Zhi-Hong Li1, Ruo-Mei Wang4, Yong-Yuan Guan1, Bin Zhang5, Guan-Lei Wang6.   

Abstract

Neutrophil extracellular traps (NETs) play crucial roles in atherosclerotic cardiovascular diseases such as acute coronary syndrome (ACS). Our preliminary study shows that oxidized low-density lipoprotein (oxLDL)-induced NET formation is accompanied by an elevated intracellular Cl- concentration ([Cl-]i) and reduced cystic fibrosis transmembrane conductance regulator (CFTR) expression in freshly isolated human blood neutrophils. Herein we investigated whether and how [Cl-]i regulated NET formation in vitro and in vivo. We showed that neutrophil [Cl-]i and NET levels were increased in global CFTR null (Cftr-/-) mice in the resting state, which was mimicked by intravenous injection of the CFTR inhibitor, CFTRinh-172, in wild-type mice. OxLDL-induced NET formation was aggravated by defective CFTR function. Clamping [Cl-]i at high levels directly triggered NET formation. Furthermore, we demonstrated that increased [Cl-]i by CFTRinh-172 or CFTR knockout increased the phosphorylation of serum- and glucocorticoid-inducible protein kinase 1 (SGK1) and generation of intracellular reactive oxygen species in neutrophils, and promoted oxLDL-induced NET formation and pro-inflammatory cytokine production. Consistently, peripheral blood samples obtained from atherosclerotic ApoE-/- mice or stable angina (SA) and ST-elevation ACS (STE-ACS) patients exhibited increased neutrophil [Cl-]i and SGK1 activity, decreased CFTR expression, and elevated NET levels. VX-661, a CFTR corrector, reduced the NET formation in the peripheral blood sample obtained from oxLDL-injected mice, ApoE-/- atherosclerotic mice or patients with STE-ACS by lowering neutrophil [Cl-]i. These results demonstrate that elevated neutrophil [Cl-]i during the development of atherosclerosis and ACS contributes to increased NET formation via Cl--sensitive SGK1 signaling, suggesting that defective CFTR function might be a novel therapeutic target for atherosclerotic cardiovascular diseases.
© 2022. The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.

Entities:  

Keywords:  CFTR; SGK1; atherosclerotic cardiovascular diseases; intracellular chloride; neutrophil extracellular traps; oxLDL

Year:  2022        PMID: 35513433     DOI: 10.1038/s41401-022-00911-9

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  40 in total

Review 1.  Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights.

Authors:  Yvonne Döring; Peter Libby; Oliver Soehnlein
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  The ClC-3 Cl- channel in cell volume regulation, proliferation and apoptosis in vascular smooth muscle cells.

Authors:  Yong-Yuan Guan; Guan-Lei Wang; Jia-Guo Zhou
Journal:  Trends Pharmacol Sci       Date:  2006-05-11       Impact factor: 14.819

Review 3.  An emerging role for neutrophil extracellular traps in noninfectious disease.

Authors:  Selina K Jorch; Paul Kubes
Journal:  Nat Med       Date:  2017-03-07       Impact factor: 53.440

4.  Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation.

Authors:  Mi Wang; Hui Yang; Ling-Yun Zheng; Zheng Zhang; Yong-Bo Tang; Guan-Lei Wang; Yan-Hua Du; Xiao-Fei Lv; Jie Liu; Jia-Guo Zhou; Yong-Yuan Guan
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

5.  Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in ST-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size.

Authors:  Andreas Mangold; Sherin Alias; Thomas Scherz; Thomas Hofbauer; Johannes Jakowitsch; Adelheid Panzenböck; Daniel Simon; Daniela Laimer; Christine Bangert; Andreas Kammerlander; Julia Mascherbauer; Max-Paul Winter; Klaus Distelmaier; Christopher Adlbrecht; Klaus T Preissner; Irene M Lang
Journal:  Circ Res       Date:  2014-12-29       Impact factor: 17.367

6.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

7.  Serum Chloride Levels Track With Survival in Patients With Pulmonary Arterial Hypertension.

Authors:  Tawfeq Naal; Batool Abuhalimeh; Ghaleb Khirfan; Raed A Dweik; W H Wilson Tang; Adriano R Tonelli
Journal:  Chest       Date:  2018-04-24       Impact factor: 9.410

8.  Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure.

Authors:  Jeffrey M Testani; Jennifer S Hanberg; Juan Pablo Arroyo; Meredith A Brisco; Jozine M Ter Maaten; F Perry Wilson; Lavanya Bellumkonda; Daniel Jacoby; W H Wilson Tang; Chirag R Parikh
Journal:  Eur J Heart Fail       Date:  2016-01-13       Impact factor: 15.534

9.  SGK1 mediates the hypotonic protective effect against H2O2-induced apoptosis of rat basilar artery smooth muscle cells by inhibiting the FOXO3a/Bim signaling pathway.

Authors:  Bao-Yi Chen; Cheng-Cui Huang; Xiao-Fei Lv; Hua-Qing Zheng; Ya-Juan Zhang; Lu Sun; Guan-Lei Wang; Ming-Ming Ma; Yong-Yuan Guan
Journal:  Acta Pharmacol Sin       Date:  2020-03-05       Impact factor: 6.150

10.  Influences of chloride and hypochlorite on neutrophil extracellular trap formation.

Authors:  Kathryn Akong-Moore; Ohn A Chow; Maren von Köckritz-Blickwede; Victor Nizet
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.